Glucagon antagonists for the treatment of Type 2 diabetes

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.9, Iss.6, 1999-06, pp. : 701-709

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Glucagon as a target for the treatment of Type 2 diabetes

By Sloop Kyle W Michael M Dodson Moyers Julie S

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 3, 2005-06 ,pp. : 593-600

Informa Healthcare

Access to resources Recommend Favorite

Treatment of Type 2 diabetes mellitus based on glucagon-like peptide-1

By Holst J.J.

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 9, 1999-09 ,pp. : 1409-1415

Informa Healthcare

Access to resources Recommend Favorite

Pharmacogenetics of Glucagon-like Peptide-1 Agonists for the Treatment of Type 2 Diabetes Mellitus

Current Clinical Pharmacology, Vol. 12, Iss. 4, 2018-04 ,pp. : 202-209

Bentham Science Publishers

Access to resources Recommend Favorite

Progress towards glucagon receptor antagonist therapy for Type 2 diabetes

By Kurukulasuriya Ravi Link JT

Expert Opinion on Therapeutic Patents, Vol. 15, Iss. 12, 2005-12 ,pp. : 1739-1749

Informa Healthcare

Access to resources Recommend Favorite

The glucagon-like peptide-1 analogue liraglutide has demonstrated promising properties for once-daily treatment of type-2 diabetes mellitus

Inpharma, Vol. 1, Iss. 1607, 2007-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite